Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients
Go back to Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients| (NASDAQ: TLSA) | Delayed: 0.97 +0.20 (25.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.77 | 52 Week High | $ | |||
| Open | $0.85 | 52 Week Low | $ | |||
| Day High | $1.01 | P/E | N/A | |||
| Day Low | $0.85 | EPS | $ | |||
| Volume | 1,752,702 | |||||
